A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial

R.A. Soo; K. Vervita; M. Früh; B.C. Cho; M. Majem; D. Rodriguez Abreu; K. Ribi; A. Callejo; T. Moran; M. Domine Gomez; M. Provencio; A. Addeo; J.Y. Han; A.L. Ortega Granados; M. Reck; A. Blasco; R. Garcia Campelo; M.A. Sala González; C. Britschgi; H. Roschitzki-Voser; B. Ruepp; A. Gasca-Ruchti; M. Haberecker; U. Dafni; S. Peters; R.A. Stahel

doi:10.1016/j.lungcan.2025.108454

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial

R.A. Soo
, K. Vervita
, M. Früh
, B.C. Cho
, M. Majem
, D. Rodriguez Abreu
, K. Ribi
, A. Callejo
, T. Moran
, M. Domine Gomez
, M. Provencio
, A. Addeo
, J.Y. Han
, A.L. Ortega Granados
, M. Reck
, A. Blasco
, R. Garcia Campelo
, M.A. Sala González
, C. Britschgi
, H. Roschitzki-Voser

B. Ruepp, A. Gasca-Ruchti, M. Haberecker, U. Dafni, S. Peters, R.A. Stahel

Careum Hochschule Gesundheit

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	108454
Fachzeitschrift	Lung Cancer
Jahrgang	202
DOIs	https://doi.org/10.1016/j.lungcan.2025.108454
Publikationsstatus	Veröffentlicht - 1 Apr. 2025

Zugriff auf Dokument

10.1016/j.lungcan.2025.108454

https://linkinghub.elsevier.com/retrieve/pii/S0169500225000753

Dieses zitieren

Soo, R. A., Vervita, K., Früh, M., Cho, B. C., Majem, M., Rodriguez Abreu, D., Ribi, K., Callejo, A., Moran, T., Domine Gomez, M., Provencio, M., Addeo, A., Han, J. Y., Ortega Granados, A. L., Reck, M., Blasco, A., Garcia Campelo, R., Sala González, M. A., Britschgi, C., ... Stahel, R. A. (2025). A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial. Lung Cancer, 202, 108454. https://doi.org/10.1016/j.lungcan.2025.108454

@article{f1b537c313e8461089b79eaea4f4a54f,

title = "A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial",

author = "R.A. Soo and K. Vervita and M. Fr{\"u}h and B.C. Cho and M. Majem and \{Rodriguez Abreu\}, D. and K. Ribi and A. Callejo and T. Moran and \{Domine Gomez\}, M. and M. Provencio and A. Addeo and J.Y. Han and \{Ortega Granados\}, A.L. and M. Reck and A. Blasco and \{Garcia Campelo\}, R. and \{Sala Gonz{\'a}lez\}, M.A. and C. Britschgi and H. Roschitzki-Voser and B. Ruepp and A. Gasca-Ruchti and M. Haberecker and U. Dafni and S. Peters and R.A. Stahel",

year = "2025",

month = apr,

day = "1",

doi = "10.1016/j.lungcan.2025.108454",

language = "English",

volume = "202",

pages = "108454",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Soo, RA, Vervita, K, Früh, M, Cho, BC, Majem, M, Rodriguez Abreu, D, Ribi, K, Callejo, A, Moran, T, Domine Gomez, M, Provencio, M, Addeo, A, Han, JY, Ortega Granados, AL, Reck, M, Blasco, A, Garcia Campelo, R, Sala González, MA, Britschgi, C, Roschitzki-Voser, H, Ruepp, B, Gasca-Ruchti, A, Haberecker, M, Dafni, U, Peters, S & Stahel, RA 2025, 'A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial', Lung Cancer, Jg. 202, S. 108454. https://doi.org/10.1016/j.lungcan.2025.108454

TY - JOUR

T1 - A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial

AU - Soo, R.A.

AU - Vervita, K.

AU - Früh, M.

AU - Cho, B.C.

AU - Majem, M.

AU - Rodriguez Abreu, D.

AU - Ribi, K.

AU - Callejo, A.

AU - Moran, T.

AU - Domine Gomez, M.

AU - Provencio, M.

AU - Addeo, A.

AU - Han, J.Y.

AU - Ortega Granados, A.L.

AU - Reck, M.

AU - Blasco, A.

AU - Garcia Campelo, R.

AU - Sala González, M.A.

AU - Britschgi, C.

AU - Roschitzki-Voser, H.

AU - Ruepp, B.

AU - Gasca-Ruchti, A.

AU - Haberecker, M.

AU - Dafni, U.

AU - Peters, S.

AU - Stahel, R.A.

PY - 2025/4/1

Y1 - 2025/4/1

U2 - 10.1016/j.lungcan.2025.108454

DO - 10.1016/j.lungcan.2025.108454

M3 - Article

SN - 0169-5002

VL - 202

SP - 108454

JO - Lung Cancer

JF - Lung Cancer

ER -